| Item type |
学術雑誌論文 / Journal Article(1) |
| 公開日 |
2021-07-01 |
| タイトル |
|
|
タイトル |
Clinical significance of serum S100 calcium binding protein A4 in idiopathic pulmonary fibrosis |
|
言語 |
en |
| 言語 |
|
|
言語 |
eng |
| キーワード |
|
|
主題 |
Biomarker |
| キーワード |
|
|
主題 |
fibroblast |
| キーワード |
|
|
主題 |
idiopathic pulmonary fibrosis |
| キーワード |
|
|
主題 |
S100A4 |
| 資源タイプ |
|
|
資源タイプ識別子 |
http://purl.org/coar/resource_type/c_6501 |
|
資源タイプ |
journal article |
| その他のタイトル |
|
|
その他のタイトル |
S100A4 in IPF |
| 著者 |
Akiyama, Norimichi
Hozumi, Hironao
Isayama, Takuya
Okada, Jun
Sugiura, Katsunori
Yasui, Hideki
Suzuki, Yuzo
Kono, Masato
Karayama, Masato
Furuhashi, Kazuki
Enomoto, Noriyuki
Fujisawa, Tomoyuki
Inui, Naoki
Nakamura, Yutaro
Suda, Takafumi
|
| 書誌情報 |
Respirology
巻 25,
号 7,
p. 743-749,
発行日 2020-07
|
| 出版者 |
|
|
出版者 |
John Wiley and Sons |
| 権利 |
|
|
権利情報 |
"This is the peer reviewed version of the following article: ""Clinical significance of serum S100 calcium binding protein A4 in idiopathic pulmonary fibrosis, Respirology; 25(7): 743-749, 2020"", which has been published in final form at ""https://doi.org/10.1111/resp.13707"". This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions." |
| 抄録 |
|
|
内容記述タイプ |
Abstract |
|
内容記述 |
Background and objective: Idiopathic pulmonary fibrosis (IPF) is a progressive interstitial lung disease with a poor prognosis. There are no established serum biomarkers for predicting the outcomes of IPF. S100 calcium binding protein A4 (S100A4) is considered a marker of fibroblasts; however, its clinical application remains to be investigated. We evaluated the clinical relevance of S100A4 in IPF patients.
Methods: Serum S100A4 levels in 95 consecutive IPF patients and 50 healthy controls (HCs) were measured using enzyme-linked immunosorbent assay. S100A4 expression in lung tissues was determined using immunohistochemistry/immunofluorescence and its association with disease progression (defined as deterioration in lung function or death) and mortality was assessed using Kaplan?Meier method and Cox hazards analysis.
Results: Serum S100A4 levels were undetectable in all HCs but were detectable in 26 (27.3%) of the 95 IPF patients (P<0.01). Immunostaining of lung tissues from IPF patients showed aggregation of numerous S100A4-expressing cells around the fibroblastic foci and mature fibrotic regions. IPF patients with higher serum S100A4 levels had a significantly worse prognosis than those with low serum levels (2-year cumulative survival rate, 41.7% vs. 77.0%, respectively, P<0.01). On multivariate analyses, baseline serum S100A4 levels (per 10 ng/mL increase) were independently associated with higher disease progression rate (odds ratio 1.06, P=0.01) and higher mortality (hazard ratio 1.18, P=0.03).
Conclusions: S100A4 is a promising serum biomarker that may help predict disease progression/mortality. Our findings may help establish treatment strategies for IPF. |
| ISSN |
|
|
収録物識別子タイプ |
ISSN |
|
収録物識別子 |
1323-7799 |
| EISSN |
|
|
収録物識別子タイプ |
ISSN |
|
収録物識別子 |
1440-1843 |
| PubMed番号 |
|
|
関連タイプ |
isVersionOf |
|
|
識別子タイプ |
PMID |
|
|
関連識別子 |
31597225 |
| 出版社DOI |
|
|
関連タイプ |
isVersionOf |
|
|
識別子タイプ |
DOI |
|
|
関連識別子 |
10.1111/resp.13707 |
| 著者版フラグ |
|
|
出版タイプ |
AM |
|
出版タイプResource |
http://purl.org/coar/version/c_ab4af688f83e57aa |
Respirology-25-743.pdf (1.2 MB)
